Modulation of human upper intestinal nutrient transit by a beta adrenoreceptor mediated pathway

A S McIntyre, D G Thompson, S Day, W R Burnham, E R Walker

Abstract

To explore the role played by beta adrenoreceptor mediated pathways on human upper gut function a series of studies were conducted into the effects of beta adrenoreceptor agonists and antagonists on oro-caecal and duodeno-caecal transit and on antral and duodenal motor activity. Under control conditions oro-caecal transit was consistent within individuals (mean coefficient of variation (18.0%) but varied widely between individuals (median transit 63 minutes, range 33-164). Prior administration of the non-selective beta adrenergic antagonist propranolol consistently hastened oro-caecal transit (median transit 51:25-93, *v* control $p < 0.005$). The selective beta-1 antagonist, atenolol, also hastened transit (median transit 50:35-93 minutes, *v* control $p < 0.01$). The magnitude of an individual's response to beta blockade correlated closely with the oro-caecal transit ($\text{Tau} = 0.54$, $p < 0.01$). Duodenocaecal transit was also hastened by propranolol from control values of 66:45-107 minutes to 50:16-62 minutes, $p < 0.025$). In contrast neither duodenal nor antral motility were consistently altered by beta blockade. The beta adrenoreceptor agonist, isoprenaline, delayed both oro-caecal transit (97:55-178 minutes, *v* control $p < 0.005$) and also duodenocaecal transit (160:45-215 minutes, *v* 73:40-133) ($p < 0.025$). Isoprenaline also reduced antral motility by an effect which appeared to occur predominantly through a reduction in contraction amplitude (from a median amplitude of 27: 5.39 mm Hg to 14: 3-24 mm Hg, $p < 0.03$) rather than an effect on the interval between contractions. No effect on either amplitude or frequency of duodenal motor activity was observed. A beta adrenoreceptor mediated pathway thus appears to exert a biologically relevant effect on gut function not only under conditions of sympathetic stimulation, but also at rest when a basal beta adrenergic tone appears to influence the speed of nutrient transit through the human upper gut.

(Gut 1992; 33: 1062-1070)

Department of
Medicine, Hope
Hospital, Salford
D G Thompson

Oldchurch Hospital,
A S McIntyre
W R Burnham

Dept of Statistics
The London Hospital,
London
S Day
E R Walker

Correspondence to:
Dr D G Thompson, Senior
Lecturer in Medicine, Hope
Hospital, Eccles Old Road,
Salford M6 8HD.

Accepted for publication
27 November 1991

The major effects of the sympathetic nervous system on the function of the human body have been well recognised since the time of Cannon.¹ Results of sympathetic pathway stimulation on the body may be classified according to responses to different catecholamines into alpha (predominantly adrenaline responsive) and beta (predominantly adrenaline responsive). Beta receptors are further divisible into beta-1 and beta-2 subtypes.²

In man beta-1 mediated effects are usually

recognised by changes in pulse rate and blood pressures whereas beta-2 specific actions induce bronchodilation and hypokalaemia.³

Although the physiological responses to sympathetic stimulation are well known for some human organ systems - for example, the cardiovascular system, responses in the human gut are less well defined. Sympathetic nervous activity has been recognised to influence motor function in the gut since Bayliss and Starling first showed inhibition of intestinal peristalsis in animals by electrical stimulation of the splanchnic nerves, and an increase in peristalsis when the nerves were divided.⁴ The distribution of sympathetic fibres to the enteric nervous system⁵ and the localisation of alpha adrenoreceptors on enteric nerves⁶ indicate that sympathetic nerves release noradrenaline into myenteric axo-axonal synapses which, through post ganglionic alpha adrenoreceptor stimulation reduce cholinergic activity in enteric nerves.⁷ In contrast, beta-adrenoreceptors do not appear to be localised on enteric nerves but have been found on gastrointestinal smooth muscle.⁸ In vitro, beta agonists inhibit contraction of isolated smooth muscle cells⁸ and electrically stimulated muscle strips⁹ whilst beta antagonists enhance contraction.

Beta adrenergic influences on intact human gastric function have been identified by Rees *et al* who showed that the beta agonist isoprenaline delayed, while the beta antagonist propranolol accelerated gastric emptying.¹⁰ Further evidence for beta adrenoreceptor modulation of human upper gut function has recently been provided in experiments showing that experimental sympathetic stimulation by hand immersion in cold water delays oro-caecal transit, an effect which is attenuated by prior administration of beta adrenoreceptor antagonist drugs.¹¹

The aim of the current series of studies was to extend the understanding of beta adrenoreceptor mediated effects on human upper gastrointestinal motor function by administering beta adrenoreceptor agonists and antagonists to normal individuals.

Three groups of studies were conducted in the following sequence. The first examined the effect of these agents on oro-caecal transit time. The second group studied effects on duodeno-caecal transit to determine whether the effects observed in the first group extended beyond the stomach. The third group of studies investigated the effects of adrenoreceptor stimulation on antral and duodenal motor activity to determine whether beta-adrenoreceptor mediated effects on transit could be exerted through an action on gastric or duodenal motor patterns. The rationale for the motility experiments was based on reports that antral motility was inhibited by experimental sympathetic stimulation, an effect

Figure 1: Cardiovascular parameters recorded during experiments number 2, 4, and 9 respectively are presented for the control studies (open circles and bars) and for the beta-antagonist studies (closed circles and hatched bars). Values represent mean and standard error.

which was attenuated by prior adrenoreceptor blockade^{11 12} while studies of beta blockade alone on motility had shown no effect.¹¹

Methods

VOLUNTEERS

All studies were conducted on healthy volunteers (age 19–34 years), drawn from medical and paramedical staff. None gave a current or past history of gastrointestinal disorder and all were accustomed to the environment of the clinical research laboratory, having performed transit studies on previous occasions. Protocols of all the studies were submitted to, and approved by, the local Ethics Committee and all the volunteers gave written informed consent before participation.

PHARMACOLOGICAL AGENTS

All the drugs used for the experiments were commercially available preparations. Propranolol (Inderal, ICI plc) was used as a non-selective beta antagonist, and was administered orally in doses ranging from 40 to 160 mg one

hour before ingestion of the test meal, this time interval having previously been found to allow development of optimal betablockade.^{11 13}

Atenolol (Tenormin 100 mg, Stuart Pharmaceuticals Ltd) was chosen for its beta-1 selective peripheral antagonist actions and was again administered orally one hour before test meal ingestion. When used to abolish the beta-1 agonist effects of isoprenaline, however, atenolol was given intravenously as a 5 mg loading dose followed by a 0.1 mg per minute intravenous infusion.

Isoprenaline (Saventrine, Pharmax Ltd), a non-selective beta agonist¹⁴ was given at doses ranging between 0.005 to 0.06 µg/kg/min by intravenous infusion. In pilot studies the beta agonist action on cardiovascular parameters was found to reach a maximum effect after 10 minutes. Infusions were thus started at least 10 minutes before ingestion of the test meal in each transit study and 10 minutes before commencement of observations in motility studies.

Salbutamol (Ventolin, Allan & Hansburys, Ltd) a beta-2 selective agonist¹⁴ was administered intravenously at a dose of 0.07 mg/kg/min. This dose was chosen on the basis of previously reported studies which indicated it to have optimal beta-2 adrenergic agonist activity (hypokalaemia) with minimal beta-1 agonist activity.³

For control experiments matching dummy tablets were supplied by the hospital

Figure 2: Cardiovascular parameters recorded during experiments number 6, 9, and 10 respectively are presented as in Figure 1 for the control studies (open circles and bars) and with isoprenaline (closed circles and hatched bars).

Figure 3: Relationship between orocaecal transit time and dose of propranolol in one subject.

pharmacy and normal saline was used for intravenous infusion.

EXTRA INTESTINAL MEASUREMENTS OF DRUG ACTIVITY

To provide a measure of the bioactivity of the drug in each study, effects on the cardiovascular system were monitored by serial measurements of radial pulse rate (beats/minute) and brachial artery blood pressure (by sphygmomanometer). The beta-2 agonist activity of salbutamol was measured by assaying serum potassium at 15 minute intervals.

OROCAECAI TRANSIT STUDIES

Orocaecal transit was determined using a previously validated and standardised breath hydrogen method.¹⁵ The test meal consisted of 425 g chicken soup (H J Heinz Ltd) to which 20 g lactulose (Duphalac, Duphar Ltd) was added as a transient marker. The meal had a total osmolality of 777 mOsmol, and contained 5.6 g protein and 11.4 g fat. Transit was measured as the interval between ingestion of the meal and the onset of a persistent rise in end expiratory breath hydrogen which at least doubled basal values. Subjects were studied after a 15 hour

Figure 4: Orocaecal transit times for 21 subjects under control conditions and after propranolol 160 mg (median values are shown by the horizontal bars).

Figure 5: Plot of the sum of, and the difference in, orocaecal transit time for control and propranolol data indicating the change in interindividual variation under the two conditions.

overnight fast which followed an evening meal low in poorly absorbed carbohydrate to ensure that basal breath hydrogen at the onset of the study was less than 20 parts per million. Activities likely to affect breath hydrogen production were avoided during the experiments,¹⁶ all of which were conducted in a quiet room with subjects in a semi-reclined position.

BETA ADRENORECEPTOR ANTAGONIST STUDIES

Experiment 1: Pilot study of the effect of propranolol on orocaecal transit

One subject performed repeated transit studies after ingestion of 40 mg, 60 mg, 80 mg, and 160 mg of propranolol on different occasions. The same individual then undertook six additional studies comparing the effect of propranolol (160 mg) with placebo, the order of the experiments being randomised.

Experiment 2: Single blind controlled study of propranolol on orocaecal transit

Based on the data obtained from the pilot study, the effect of propranolol (160 mg) on orocaecal transit time was compared with placebo in 21 volunteers (age 19–34 years; 17 men) using a single blind randomised order design.

Figure 6: Results of the repeat studies on the 11 subjects are shown under control and propranolol pretreated conditions.

Figure 7: Individual oro-caecal transit times in seven individuals under either control conditions or beta adrenergic blockade with either propranolol (beta 1 and 2 antagonist) or atenolol (a selective beta 1 antagonist).

Experiment 3: Repeatability studies

Eleven of the subjects who performed experiment 2 ingested 160 mg propranolol or placebo on two to five occasions each, in randomised order, following an identical protocol to experiment 2 to determine the degree of intraindividual variation of the response.

Experiment 4: Effect of atenolol on oro-caecal transit

To investigate the beta adrenoreceptor subtype involved in control of oro-caecal transit, seven of the subjects who participated in the propranolol study (experiment 2) repeated the protocol using the more beta-1 specific antagonist atenolol.

BETA ADRENORECEPTOR AGONIST STUDIES

Experiment 5: Pilot study of the effect of isoprenaline on oro-caecal transit

Seven studies were performed in one individual using isoprenaline at doses of 0.005, 0.015, 0.03 and 0.06 $\mu\text{g/kg/min}$ to construct a dose response curve. The same subject then underwent six further studies comparing 0.015 $\mu\text{g/kg/min}$ with saline in randomised order.

Figure 8: Relationship between oro-caecal transit time and dose of isoprenaline. Symbols represent individual values in one individual.

Figure 9: Oro-caecal transit time for 19 subjects under control conditions and during isoprenaline infusion (horizontal bars indicate median values).

Experiment 6: Single blind controlled study of isoprenaline on oro-caecal transit

Isoprenaline 0.015 $\mu\text{g/kg/min}$ was compared with saline infusion in 19 volunteers (age 19–33 years; 16 men) in a single blind randomised order study. This dose was selected because it produced a marked change in transit in the pilot study without major changes in cardiovascular variables. A previous study had also shown this dose to be capable of altering fluid and electrolyte movement across the gastrointestinal mucosa.¹⁷

Experiment 7: Repeatability studies

Eight subjects who had participated in experiment 6 repeated both the isoprenaline and saline infusion studies on two to four occasions in randomised order to assess the repeatability of the isoprenaline effect.

Experiment 8: Studies on the adrenoreceptor subtype involved in the adrenoreceptor agonist effect (a) Effect of atenolol on isoprenaline induced oro-caecal transit delay

To determine whether the beta-1 selective antagonist atenolol would abolish any delaying effect of isoprenaline on oro-caecal transit, two of the subjects who had participated in experiment 6 received an infusion of the drug together with either intravenous atenolol, or saline in a single blind randomised order study.

(b) Effect of salbutamol on oro-caecal transit

To further investigate the role of beta adrenoreceptor subtypes in the agonist effect salbutamol, a more selective beta-2 agonist was administered intravenously to the same two

subjects who participated in experiment 8a, using a similar protocol to that for experiment 6.

DUODENOCAECAL TRANSIT STUDIES

Before each study, all subjects were prepared in an identical manner to the oro-caecal transit experiments. On arrival in the study unit, a fine bore feeding tube (external diameter 2 mm) was swallowed and positioned with the aid of fluoroscopic imaging so that its tip was in the second part of the duodenum. Transit was defined as the interval between time of administration of 100 ml of an isoosmolar lactulose test solution (delivery slowly into the duodenum over three minutes to minimise intraluminal distension) to the onset of a sustained breath hydrogen rise.

Experiment 9: Single blind controlled studies of propranolol or isoprenaline on duodenocaecal transit

These studies were designed to explore the effect of beta antagonists and agonists on small intestinal transit. The effect of propranolol was compared with placebo in six subjects, while in six further subjects the effect of an isoprenaline infusion was compared with saline infusion.

ANTRODUODENAL MOTILITY STUDIES

Volunteers attended the laboratory after a preparation identical to that used for the oro-caecal transit studies. Each swallowed a multilumen manometry tube which was positioned fluoroscopically so that two distal ports lay in the second and third part of the duodenum, while eight further ports, situated at 1 cm intervals, lay on either side of the pylorus. Positioning of the juxtapyloric ports was aided by the tube design which had a central radio opaque channel and radio opaque markers beside each port. After the identification of the irregular motor pattern characterising phase II

activity, subjects ingested a standard meal to induce postprandial motor activity. The meal was ingested over a 10 minute period and the tube adjusted if necessary over the subsequent three minutes to establish optimum recording conditions. Drug infusions were then started and after a further 10 minutes manometric activity was collected for analysis for a 15 minute period.

For detection of antral and duodenal motility patterns, each lumen was continuously perfused pneumohydraulically and connected to a strain gauge transducer (Gaeltec Ltd, Dunvegan, Skye, Scotland), its output then being fed into a chart recorder (Wanatabe Linearcorde Mark VII, Tokyo, Japan) to provide a permanent record.

Each individual performed two studies per study day to minimise radiation exposure. The second study was always started at least three hours after ingestion of the first meal, after the recurrence of a phase III pattern, characteristic of fasting motor activity and, after the return of cardiovascular variables to the basal state.

Experimental 10: Effect of isoprenaline on antroduodenal motility

The effect of isoprenaline on antroduodenal motility was compared with saline infusion in a single blind randomised order experiment. Each infusion started three minutes after ingestion of the meal and was given for 10 minutes before the observation period and for the duration of the 15 minute study period (giving a total infusion duration of 25 minutes).

DATA ANALYSIS

Cardiovascular data

The effect of beta agonists and antagonists on pulse and blood pressure were compared with control values using Student's paired *t* test¹⁸ and are reported as mean and standard error of the mean.

Transit data

In the studies of oro-caecal and duodenocaecal transit, the effect of the active drug was compared with placebo using Wilcoxon's paired sign rank test or Pratt's sign test (if $n < 7$).¹⁹ Because the measured variable may not be normally distributed results are reported as median and range. Correlations were determined using Kendall's rank correlation coefficient (Tau).¹⁹

The reproducibility of the test in each individual was calculated as the coefficient of variation, and reproducibility in the group is presented as the mean coefficient of variation.¹⁸

Antroduodenal motility data

Contractions were defined as those intraluminal pressure changes which could be distinguished from the respiratory artefact, excluding those which occurred synchronously in several channels and which could have been extra-intestinal in origin. Antral activity was analysed from the most distal of the antral ports which

Figure 10: Repeat studies on eight subjects are shown both under control conditions and during isoprenaline infusion.

provided evaluable data during the study. Duodenal activity was obtained from the most distal channel sited in the second part of the duodenum.

Motor activity was analysed for a 15 minute period, beginning 13 minutes after completion of meal ingestion to ensure a consistent feeding pattern. The variables chosen for analysis were, the mean amplitude of intraluminal pressure activity (mm Hg) and the intercontraction interval (seconds). The differences between test and control values were compared using Pratt's sign test.¹⁹

Results

EXTRINTESTINAL EFFECTS OF BETA AGONISTS AND BETA ANTAGONISTS

Propranolol and atenolol produced the expected reduction in pulse rate, systolic blood pressure and diastolic blood pressure in all individuals studied (Fig 1). No side effects were observed in any subjects in the beta antagonist studies. Isoprenaline increased the pulse rate, raised systolic, and reduced diastolic, blood pressure in each of the studies (Fig 2). Subjects were aware of mild palpitations during all but the lowest dose of isoprenaline. As expected, coadministration of atenolol completely abolished the cardiovascular changes produced by isoprenaline. Salbutamol reduced the serum potassium (mean change 0.36 mmol/l SEM=0.09, $p<0.01$) showing beta-2 agonist activity, but the cardiovascular parameters also changed, with a rise in systolic blood pressure (mean rise 13 mm Hg) suggesting concomitant beta-1 agonist effects at the dose used.

BETA ADRENORECEPTOR ANTAGONIST EFFECTS ON OROCAECAL TRANSIT

In the pilot study (experiment 1) propranolol consistently hastened transit compared with control values, the response being dose related (Fig 3).

The results of experiment 2 showed a wide interindividual difference in control orocaecal transit time values ranging from 30–164 minutes (Fig 4). Propranolol hastened orocaecal transit compared with the control studies (from 63:30–164 to 51:25–93 minutes, $p<0.005$). The acceleration induced by propranolol was greatest in those subjects with the longest orocaecal transit times, a direct correlation being found between control transit and degree of acceleration $\text{Tau}=0.58$, $p<0.01$).

Unfortunately, it is not possible to determine with any certainty what proportion of interindividual variation is dependent on the beta adrenoreceptor mediated pathway by comparing the difference in slope of the regression line with the line of intent because the error in control transit measurement will contribute an unknown reduction in the gradient. The extent to which variation in beta adrenoreceptor blockade induced acceleration, and hence might contribute to interindividual variability, can however be calculated by the method described by Bland.²⁰ This consists of first showing a significant change

in variation between control and test conditions, and second using the proportion of the variances as a measure of the beta adrenergic contribution. The relationship of the difference between and the sum of the test and control values was determined for all individuals. There was a good correlation between the control test value difference, and the sum of the two values for an individual ($r=0.67$) indicating a significant change in variance ($p<0.001$) (Fig 5). The contribution of the beta adrenergic component to interindividual variation was calculated from the ratio of the variances (418/1148) and indicated that 36% of the interindividual differences could be attributed to the variable activity of the beta adrenoreceptor mediated pathway.

The results of the repeat studies (experiment 3) show that administration of propranolol was consistently associated with reduction in transit (Fig 6). Intraindividual variation also fell slightly with transit acceleration, the mean coefficient of variation falling from 18% (SEM 4%) to 10% (SEM 2.7%).

Administration of atenolol (experiment 4) also hastened orocaecal transit from a median value of 100: (range 45–164) minutes to 50: (range 35–93) minutes, $p<0.01$. This hastening was similar in magnitude to that induced by propranolol (45:30–93 minutes) (Fig 7), the mean difference between the degree of acceleration produced by the two drugs being 1.47 minutes.

BETA ADRENORECEPTOR AGONIST EFFECTS ON OROCAECAL TRANSIT

In the pilot study (experiment 5) Isoprenaline consistently delayed orocaecal transit, the magnitude of the delay increasing with dose administration (Fig 8).

In the group study (experiment 6) isoprenaline 0.015 $\mu\text{g/kg/min}$ consistently delayed orocaecal

Figure 11: Mean orocaecal transit times and cardiovascular changes are shown in two individuals (subject 1=open symbols, subject 2=closed symbols) during control and beta agonist studies to show attenuation of the isoprenaline effect by atenolol and also the non-specific beta agonist effect of salbutamol at the dose used.

Figure 12: Accelerating effect of propranolol on duodenocaecal transit time (median values shown by horizontal bars).

transit, the rate during test infusion being slowed to 97 (range 55–178 minutes compared with the control values of 58 (40–165) minutes, $p < 0.01$ (Fig 9).

Unlike the beta antagonists study, however, no relationship was found between the magnitude of the drug effect and oro-caecal transit ($\text{Tau} = 0.09$, $p > 0.1$).

The isoprenaline induced transit delay was consistently reproduced in all the subjects when the study was repeated (experiment 7) (Fig 10).

Concomitant administration of atenolol and isoprenaline (experiment 8a) completely abolished the isoprenaline induced transit delay (control 45, 61 minutes: isoprenaline, 70, 105 minutes: isoprenaline+atenolol 45, 62 minutes), indicating that the isoprenaline effect was mediated by a beta-1 adrenoceptor pathway (Fig 11).

Infusion of the beta-2 agonist salbutamol (experiment 8b) did delay oro-caecal transit (control 45, 61 minutes, salbutamol 59, 92 minutes) (Fig 11). Concomitant rise of systolic blood pressure during infusion, however, indicated that beta-1 agonist activity was also present, and it was therefore not possible to exclude the possibility that the changes in oro-caecal transit observed were related to the drugs beta-1 agonist effect.

DUODENOCAECAL TRANSIT STUDIES

Propranolol consistently hastened duodenocaecal transit from 66:45–107 minutes under control conditions to 49:5–16:62 minutes after

Figure 13: Delaying effect of isoprenaline on duodenocaecal transit time (median values shown by horizontal bar).

propranolol ($p < 0.025$) (experiment 9) (Fig 12).

Isoprenaline consistently delayed duodenocaecal transit from 72:5:40–133 minutes to 160:45–215 minutes ($p < 0.025$) (Fig 13).

ANTRODUODENAL MOTILITY STUDIES

Isoprenaline reduced the mean amplitude of antral contractions from control values of 27 mm Hg (range 5–39) to 14 mm Hg (range 3–24), $p < 0.03$ (experiment 10) (Fig 14). In contrast the interval between successive antral pressure waves was unchanged by isoprenaline (control intercontraction interval 19 seconds (range 7–142) *v* 19 seconds (range 7–336) (Fig 15). In the duodenum, no evidence was found to suggest that isoprenaline affected either intercontraction interval (control 17 (range 10–20 seconds) *v* isoprenaline 17 (range 11–39 seconds), $p > 0.05$) or amplitude, control 10 (range 7–19) *v* isoprenaline 10 (range 5–5) mm Hg (Fig 14).

Discussion

In his classical study of the differential responses of mammalian tissue to various adrenoceptor agonists, Ahlquist designated receptors in the gut to the alpha subtype,²¹ although with the advent of a selective beta adrenergic agonist he subsequently also showed the presence of beta adrenoceptors.²² In man, muscle strips from the stomach and the small intestine have been shown to possess beta adrenoceptors which act in such a way that beta agonists relax, whilst beta antagonists enhance, muscle contraction.⁹ Similar results have also been obtained using

Figure 14: Effect of isoprenaline on antral and duodenal pressure is shown in six subjects.

isolated smooth muscle cells from the gastrointestinal tract indicating the presence of adrenoreceptors on smooth muscle.²³

Alpha adrenoreceptors appear to inhibit gut motor function by attenuating cholinergic and serotonergic myenteric neural activity through axo axonal synapses.²⁴ In contrast, beta adrenoreceptors do not appear to be present in the myenteric plexus.²⁵ Sympathetic neural stimulation thus appears to inhibit gut motor activity through an alpha adrenoreceptor mediated pathway, which reduces enteric neurally mediated excitation and through beta adrenoreceptors which appear to act directly on smooth muscle. Although there are relatively few sympathetic nerves which terminate in smooth muscle, clearance mechanisms to abolish the transmitter function of released noradrenaline appear relatively inefficient in the gut²⁶ so that diffusion of neurotransmitter outside the immediate vicinity of the synapse is likely to

Figure 15: Frequency histogram of the interval between successive antral contractions comparing isoprenaline (closed circles) with control infusion (open circles). It can be seen that the mode occurs at 19 seconds with a second peak at 38 seconds.

permit smooth muscle beta receptor activation.

Our demonstration of a hastening of oro-caecal transit by beta adrenoreceptor antagonists indicates the presence of a tonically active inhibitory beta adrenoreceptor mediated pathway in man. This observation is consistent with animal studies involving splanchnic nerve section^{4,27} or guanethidine induced adrenergic neuronal blockade²⁸ which have also suggested the presence of a tonic sympathetic neural inhibition of motility. The fact that subjects with longer transit accelerate more than those with rapid transit after beta blockade and that the normally wide interindividual variation in oro-caecal transit is greatly reduced suggests furthermore that the beta adrenoreceptor mediated inhibitory influence on transit is expressed to differing degrees by different individuals, while the similarity of the response in each individual indicates that the magnitude of this inhibition is consistently expressed.

The finding that isoprenaline delays oro-caecal transit is again consistent with previous animal studies where splanchnic nerve stimulation has been shown to inhibit motor activity.⁴ In addition, human studies using experimental stressors known to activate sympathetic pathways similarly delay oro-caecal transit,¹¹ an effect which can be attenuated by previous beta blockade. Unlike the adrenoreceptor antagonist studies, however, the magnitude of response to isoprenaline did not appear to be related to unstimulated transit rate. The most likely reason for this appears to be that the dose of isoprenaline, used in the study was too low for the effect to be demonstrated. While it is possible to obtain virtually total beta-blockade in man without hazard, pharmacological beta adrenoreceptor stimulation is limited by untoward cardiovascular effects.¹⁴ At the relatively low dose used in our studies we may not have provided sufficient stimulation to disclose interindividual variation in response. This suggestion is supported by our inability to reach a plateau phase in our isoprenaline transit dose response study before side effects developed.

The exact anatomical site or sites of action of the beta receptors which are modulating the transit effects is difficult to identify from the current data. Previous studies have shown effects on gastric function with acceleration of emptying during beta blockade and retardation by isoprenaline.¹⁰ Our duodenocaecal transit studies which show a similar pattern of response to those exerted on the stomach suggest that the effects may be exerted throughout the small intestine as well as the stomach. Unfortunately, because of the necessary difference in meal constituents and experimental method it is not possible to directly compare the results of the oro-caecal transit data with the duodenocaecal transit data and so the relationship between the two parameters or the relative size of the effect at the gastric or small intestinal level remains uncertain.

It is possible, however, that the small intestine is not equally responsive throughout its length. In animal experiments the ileum appears to be under greater sympathetic inhibitory control than the jejunum²⁸ and the same may be true in man. More selective studies of jejuno-caecal and

ileocaecal transit will thus be required to further elucidate this problem.

It is also uncertain by which mechanism the adrenoreceptor modulation of small intestinal transit is achieved. The lack of observed effects of isoprenaline on the pattern of motor activity and the previously reported absence of effect of beta antagonists on antroduodenal motor pattern¹¹ do not indicate a major action on contractile rhythmicity. It must be accepted, however, that the technique of intraluminal manometry, as usually performed, is relatively crude and does not permit precise assessment of aboral propagation of small intestinal contractions and intraluminal content particularly after feeding. Further studies with closely spaced sensors, or techniques capable of directly measuring intraluminal force, such as those recently developed for the oesophagus,²⁹ will be required to answer such questions.

It is also possible that the beta adrenoreceptor mediated effects on transit were achieved through a direct effect on smooth muscle tone rather than motor pattern. This hypothesis is consistent with pharmacological localisation of beta-1 adrenoreceptor effects on smooth muscle particularly longitudinal muscle³⁰ rather than the myenteric plexus, and with the observed inhibition by isoprenaline of contraction amplitude, but not contraction pattern.

The observed transit effects might additionally have been mediated by modulation of another neuroactive agent, – for example, somatostatin,³¹ or through an increase in intraluminal flow secondary to changes in epithelial,¹⁷ or pancreatic secretion.³²

In conclusion, our studies appear to have uncovered the presence of a tonically active beta adrenergically mediated pathway which operates to modulate nutrient transit in normal subjects and which varies in degree of expression between individuals. Explanations for this consistent variation in beta adrenergic tone include inter individual variation in sympathetic neuronal traffic, receptor numbers, receptor sensitivity, or end organ responsiveness. Further exploration of these possibilities is now indicated.

DGT was a Wellcome Trust Senior Lecturer in Medicine. The authors would like to thank Mrs Julie Young and Mrs Janice Hamilton for manuscript preparation.

- 1 Cannon WB. *Bodily changes in pain, hunger, fear and rage*. New York: Appleton, 1929.
- 2 Lands AM, Arnold A, AcAuliff JP. Differentiation of receptor systems activated by sympathomimetic amines. *Nature* 1967; 214: 597–8.
- 3 Brown MJ, Brown DC, Murphy MB. Hypokalaemia from beta-2 receptor stimulation by circulating epinephrine. *N Engl J Med* 1983; 309: 1414–9.
- 4 Bayliss WM, Starling EH. The movements and innervation of the small intestine. *J Physiol* 1899; 24: 99–143.
- 5 Llewellyn-Smith IJ, Furness JB, O'Brien PE, Costa M. Noradrenergic nerves in human small intestine distribution and ultrastructure. *Gastroenterology* 1984; 87: 513–29.
- 6 Gillespie JS, Khoyi MA. The site and receptors responsible for the inhibition of sympathetic nerves of intestinal smooth muscle and its parasympathetic motor nerves. *J Physiol* 1977; 267: 767–89.
- 7 Vizi ES, Knoll J. The effects of sympathetic nerve stimulation and guanethidine on parasympathetic neuro-effector transmission; the inhibition of acetylcholine release. *J Pharmacol* 1971; 23: 918–25.
- 8 Makhlof GM. Isolated smooth muscle cells of the gut. In: Johnson LR, ed. *Physiology of the gastrointestinal tract*. 2nd ed. New York: Raven Press, 1987.
- 9 Hedges A, Turner P. Beta receptors in human isolated smooth muscle. *Br J Pharmacol* 1969; 37: 547–8.
- 10 Rees MR, Clark RA, Holdsworth CD, Barber DC, Howlett PJ. The effects of beta-adrenoreceptor agonists and antagonists on gastric emptying in man. *Br J Clin Pharmacol* 1980; 10: 551–4.
- 11 O'Brien JD, Thompson DG, Day SJ, Burnham WR, Walker E. Perturbation of upper gastrointestinal transit and antroduodenal motility by experimentally applied stress: the role of beta-adrenoreceptor mediated pathways. *Gut* 1989; 30: 1530–9.
- 12 Stangellini V, Malagelada JR, Zinsmeister AR, Go VLW, Kao PC. Effect of opiate and adrenergic blockers on the gut motor response to centrally acting stimuli. *Gastroenterology* 1984; 87: 1104–13.
- 13 Hegarty AM, Castleden CM, Patel L. Failure of ranitidine to interact with propranolol. *BMJ* 1982; 284: 1304.
- 14 Innes IR, Nickerson M. Norepinephrine, epinephrine and the sympathomimetic amines. In: Goodman LS, Gilman A, eds. *The pharmacological basis of therapeutics*. 5th ed. New York: Macmillan, 1975.
- 15 O'Brien JD, Thompson DG, Burnham WR, Holly J, Walker E. The action of centrally mediated autonomic stimulation on human upper gastrointestinal transit: a comparative study of two stimuli. *Gut* 1987; 28: 960–9.
- 16 Thompson DG, Binfield P, De Belder A, O'Brien J, Warren S, Wilson M. Extra intestinal influences on exhaled breath hydrogen measurements during the investigation of gastrointestinal disease. *Gut* 1985; 26: 1349–52.
- 17 Morris AL, Turnberg LA. Influence of isoproterenol and propranolol on human intestinal transport in vivo. *Gastroenterology* 1981; 81: 1076–9.
- 18 Armitage P, Berry G. Statistical methods in medical research. 2nd ed. London: Blackwell, 1987.
- 19 Siegal S, Castellan NJ. Non parametric statistics for the behavioural sciences. 2nd ed. New York: McGraw Hill, 1988.
- 20 Bland M. *An introduction to medical statistics*. Oxford: Oxford University Press, 1987.
- 21 Ahlquist RP. A study of the adrenotropic receptors. *J Physiol* 1948; 153: 586–600.
- 22 Ahlquist RP, Levy B. Adrenergic receptive mechanism of canine ileum. *J Pharmacol Exp Ther* 1959; 127: 146–9.
- 23 Scheid CR, Honeyman TW, Fay FS. Mechanism of beta adrenergic relaxation of smooth muscle. *Nature* 1979; 277: 32–6.
- 24 Furness JB, Costa M. *The enteric nervous system*. London: Churchill Livingstone, 1987.
- 25 Taniyama K, Kuno T, Tanak C. Distribution of beta-adrenoreceptors associated with cAMP-generating system in cat colon. *Am J Physiol* 1987; 253: G378–82.
- 26 Boullin DJ, Costa E, Brodie BB. Evidence that blockade of adrenergic receptors causes overflow of noropinephrine in cats colon after nerve stimulation. *J Pharmacol Exp Ther* 1967; 157: 125–34.
- 27 Roman C, Gonelli J. Extrinsic control of digestive tract motility. In: Johnson LR, ed. *Physiology of the gastrointestinal tract*. New York: Raven Press, 1981: 289–333.
- 28 Kewenter J. The Vagal control of jejunal and ileal motility and blood flow. *Acta Physiol Scand* 1965; 257 (suppl): 1–68.
- 29 Williams D, Thompson DG, Marple M, O'Hanrahan T, Bancewicz J. Direct measurement of distention induced oesophageal clearance forces in normal volunteers and in reflux oesophagitis. [Abstract] *Gastroenterology* 1989; 96: A546.
- 30 Fox D, Herman J, Bass P. Differentiation between myenteric plexus and longitudinal muscle of the rat jejunum as the site of action of putative enteric neurotransmitters. *Eur J Pharmacol* 1986; 131: 39–47.
- 31 Summers RW, Flatt A, Yandu RJ, Yamada T. Isoproterenol induces activity fronts in fed dogs through somatostatin release. *Gastroenterology* 1984; 87: 999–1003.
- 32 Varga G, Papp M, Vizi SE. Adrenergic control of pancreatic enzyme secretion in rats. *Dig Dis Sci* 1989; 34: 988.